Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM6B | O15054 | 4/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 4/20 | 0.41 |
| ▸ | KDM2B | Q8NHM5 | 4/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.41 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.41 |
| ▸ | KDM6A | O15550 | 3/20 | 0.41 |
| ▸ | KDM5C | P41229 | 3/20 | 0.41 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.41 |
| ▸ | KDM4A | O75164 | 2/20 | 0.41 |
| ▸ | KDM4B | O94953 | 2/20 | 0.41 |
| ▸ | KDM3A | Q9Y4C1 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | KDM5A | P29375 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2237295 | 0.80 | CYP2A6 (0.45) | KDM6BKDM5BKDM2BKDM4CPHF8 | |
| SCHEMBL4771450 | 0.79 | NPC1 (0.52) | KDM4ECYP3A4CYP2C9HDAC1NPC1 | |
| SCHEMBL2240945 | 0.78 | GBA1 (0.54) | PIK3CAPIK3CBPIK3CGPTGDRCYP3A4 | |
| SCHEMBL2238098 | 0.78 | PTGDR (0.53) | KDM4EPIK3CAPIK3CBPIK3CGPTGDR | |
| SCHEMBL2241460 | 0.77 | CDK4 (0.47) | PTGDRCYP3A4CYP2C9NPC1TP53 | |
| SCHEMBL2243750 | 0.76 | PTGDR (0.41) | KDM4CPTGDRCYP3A4CYP2C9NPC1 | |
| SCHEMBL2237320 | 0.76 | HIF1A (0.47) | KDM6BKDM5BKDM2BKDM4CPHF8 | |
| SCHEMBL4773623 | 0.75 | CYP3A4 (0.48) | PIK3CAPIK3CBPIK3CGPTGDRCYP3A4 | |
| SCHEMBL3962080 | 0.75 | CDK4 (0.58) | PTGDRCYP3A4CYP2C9HDAC1NPC1 | |
| SCHEMBL2242475 | 0.75 | PTGDR (0.54) | KDM4EPIK3CAPIK3CBPIK3CGPTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044056-B1 | PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS | NOVARTIS AG (CH) | 2012-08-22 | — | — | EP | claimed |
| US-7989458-B2 | Pyrimidine derivatives as alk-5 inhibitors | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | claimed |
| US-20090209539-A1 | Pyrimidine derivatives as alk-5 Inhibitors | NOVARTIS AG (CH) | 2009-08-20 | — | — | US | claimed |
| EP-2044056-A1 | PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS | Novartis Ag (CH) | 2009-04-08 | — | — | EP | claimed |
| WO-2008006583-A1 | PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS | NOVARTIS AG (CH) | 2008-01-17 | — | — | WO | claimed |
| EP-2044056-B1 | PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS | NOVARTIS AG (CH) | 2012-08-22 | — | — | EP | disclosed |
| US-7989458-B2 | Pyrimidine derivatives as alk-5 inhibitors | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | disclosed |
| US-20090209539-A1 | Pyrimidine derivatives as alk-5 Inhibitors | NOVARTIS AG (CH) | 2009-08-20 | — | — | US | disclosed |
| EP-2044056-A1 | PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS | Novartis Ag (CH) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008006583-A1 | PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS | NOVARTIS AG (CH) | 2008-01-17 | — | — | WO | disclosed |
| EP-1878733-A1 | Pyrimidine derivatives as ALK-5 inhibitors | Novartis AG (CH) | 2008-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209539-A1 | Pyrimidine derivatives as alk-5 Inhibitors | ALK, ACVR1, MUSK | KDM6B 325/4885KDM5B 145/4885KDM2B 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.